Avalyn Pharma Inc.
Ownership
Ownership Structure
Who owns Avalyn Pharma Inc. (AVLN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 61.8% of the shares are freely tradable; institutional investors hold 66.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 13.16 | 5,835,259 | +0.0 | 06/30/2026 |
| Novo A/S | 8.76 | 3,883,289 | +0.0 | 06/30/2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 7.46 | 3,308,649 | +0.0 | 06/30/2026 |
| Perceptive Advisors LLC | 6.03 | 2,675,296 | +0.0 | 06/30/2026 |
| Suvretta Capital Management, LLC | 5.65 | 2,503,109 | +0.0 | 06/30/2026 |
| NVP Associates LLC | 5.12 | 2,268,404 | +0.0 | 06/30/2026 |
| Wellington Management Company LLP | 4.97 | 2,201,986 | +0.0 | 06/30/2026 |
| T. Rowe Price Associates, Inc. | 3.91 | 1,735,231 | +0.0 | 06/30/2026 |
| Catalio Capital Management, LP | 3.78 | 1,675,830 | +0.0 | 06/30/2026 |
| T. Rowe Price Investment Management,Inc. | 3.62 | 1,602,745 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Fmr Llc | 10% Owner | 2,056,081 | 62,916,079 $ | Nov 10, 2026 | indirect |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Fmr Llc | 10% Owner | Sell | 47,889 | 30.28 | 1,450,079 |
| Nov 10, 2026 | Fmr Llc | 10% Owner | Sell | 5,565 | 29.56 | 164,501 |
| Nov 9, 2026 | Fmr Llc | 10% Owner | Sell | 1,339 | 29.75 | 39,835 |
| Nov 9, 2026 | Fmr Llc | 10% Owner | Sell | 173,661 | 29.06 | 5,046,589 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.